Genmab A/S services

Increasingly, data are transforming our understanding of diseases. This is especially true in cancer. We have invested in robust data science capabilities to enable rapid data-driven decision making as we advance our products through all stages of development. Integration of disparate data sets from clinical and pre-clinical studies is a major guiding principle that is allowing us to extract novel insights regarding targets, investigational products, indications and patient biomarkers.

We aim to invent, develop and commercialize differentiated antibody-based products, which can be utilized in a modular fashion to create unique and tailored therapeutics to transform cancer treatments.

Using our antibody expertise to transform how cancer is treated; As a leader in the discovery and development of antibody therapeutics, we are inspired by nature, passionate about innovation and driven by data. Our commitment to patients pushes us to use our antibody biology expertise to pursue and produce differentiated, next-generation cancer treatments. Our research and innovation teams consist of a strong antibody discovery engine connecting our antibody platform technologies with our target and disease biology knowledge. This synergy is the lifeblood of our R&D organization, where our creations enter clinical development.